Drug combo reverses coronary plaques to lowest levels yet

World-first results: Researchers have found a drug combination that reduces coronary atherosclerosis more effectively than statins alone In an Australian-led multicenter, double-blind, placebo-controlled, randomised clinical trial, researchers have discovered that a cholesterol-lowering PCSK9 inhibitor called evolocumab could be key in reducing coronary plaque build-up. The GLAGOV trial was conducted at 197 academic and community hospitals across

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Sector woes not enough to reduce Tax Office penalty
Next Clinical tips: HIV/AIDS